Search Results - "Carles Reverter, Joan"

Refine Results
  1. 1

    Is antivitamin K reversal required in patients with cirrhosis undergoing liver transplantation? by Martinez, Samira, Garcia, Isabel, Ruiz, Angel, Tàssies, Dolors, Reverter, Joan Carles, Colmenero, Jordi, Beltran, Joan, Fondevila, Constantino, Blasi, Annabel

    Published in Transfusion (Philadelphia, Pa.) (01-10-2021)
    “…Background Antivitamin K agent (AVK) reversal in patients with cirrhosis awaiting liver transplantation (LT) is not defined in guidelines. We investigated the…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Study of the analytical performance at different concentrations of hematological parameters using Spanish EQAS data by Molina, Angel, Alcaraz, José, Guiñón, Leonor, Pérez, Aránzazu, Segurana, Anna, Reverter, Joan Carles, Bedini, Josep Lluís, Merino, Anna

    Published in Clinical chemistry and laboratory medicine (26-11-2019)
    “…Background External quality assessment programs are one of the currently available tools to evaluate the analytical performance of clinical laboratories, where…”
    Get more information
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8

    Venous Thrombotic Events After Liver Transplantation by Blasi, Annabel, Hernandez, Virginia, Fernandez, Javier, Colmenero, Jordi, Beltran, Joan, Garcia-Valdecasas, Juan Carlos, Reverter, Joan Carles

    Published in Clinical and applied thrombosis/hemostasis (01-03-2018)
    “…Thromboprophylaxis is not well defined after liver transplantation (LT). The aim of this study was to evaluate the incidence of splanchnic vein thrombosis…”
    Get full text
    Journal Article
  9. 9

    Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent by GARCIA-SEGARRA, Gloria, ESPINOSA, Gerard, TASSIES, Dolors, ORIOLA, Josep, AIBAR, Jesus, BOVE, Albert, CASTRO, Pedro, REVERTER, Joan-Caries, NICOLAS, Josep-Maria

    Published in Intensive care medicine (01-08-2007)
    “…To evaluate the effect of the 4G/5G PAI-1 gene polymorphism on the development of organ failure and outcome in critically ill patients with septic syndromes…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels by de la Red, Gloria, Tàssies, Dolores, Espinosa, Gerard, Monteagudo, Joan, Bové, Albert, Plaza, Joan, Cervera, Ricard, Reverter, Joan-Carles

    Published in Thrombosis and haemostasis (01-02-2009)
    “…Recent reports have described the factor XIII A subunit (FXIII-A) Val34Leu polymorphism as a protective factor against venous and arterial thrombosis. The aim…”
    Get more information
    Journal Article
  12. 12
  13. 13

    Enzyme-linked immunosorbent assays for therapeutic drug monitoring coumarin oral anticoagulants in plasma by Salvador, J.-Pablo, Tassies, Dolors, Reverter, Joan-Carles, Marco, M.-Pilar

    Published in Analytica chimica acta (22-10-2018)
    “…The development of high-throughput immunochemical assays to assist on precision medicine for patients treated with coumarin oral anticoagulants (OA) is…”
    Get full text
    Journal Article
  14. 14

    Impact of Continuous Estroprogestin Treatment on Circulating Microparticle Levels in Deep Endometriosis Patients by Carrillo Torres, Pilar, Martínez-Zamora, María Ángeles, Tàssies, Dolors, Castillo, Helena, Gracia, Meritxell, Feixas, Georgina, Reverter, Joan Carles, Carmona, Francisco

    “…There has been increasing interest in the study of new pathogenic mechanisms in endometriosis (END), including the coagulation/fibrinolysis system and its link…”
    Get full text
    Journal Article
  15. 15

    The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome by Plasín-Rodríguez, Miguel Angel, Rodríguez-Pintó, Ignasi, Patricio, Patricia, Monteagudo, Joan, Cervera, Ricard, Reverter, Joan Carles, Espinosa, Gerard, Tàssies, Dolors

    Published in Thrombosis research (01-09-2018)
    “…Genetic variants in the endothelial protein C receptor gene (PROCR) may contribute to the thrombosis risk by regulating levels of the soluble form of this…”
    Get full text
    Journal Article
  16. 16

    Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus by Plasín-Rodríguez, Miguel Angel, Patricio, Patricia, Monteagudo, Joan, García-Criado, Angeles, Cervera, Ricard, Reverter, Joan Carles, Espinosa, Gerard, Tàssies, Dolors

    Published in Journal of thrombosis and thrombolysis (01-07-2021)
    “…Microparticles (MPs) have been associated with inflammatory and thrombotic disease. High levels of MPs have been identified in patients with systemic lupus…”
    Get full text
    Journal Article
  17. 17

    ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Noninfectious Systemic Inflammatory Response Syndrome by Aibar, Jesús, Castro, Pedro, Espinosa, Gerard, Fernández, Sara, Hernández, Cristina, Rinaudo, Mariano, Butjosa, Montserrat, Tàssies, Dolors, Reverter, Joan Carles, Nicolás, Josep Maria

    Published in Shock (Augusta, Ga.) (01-06-2015)
    “…ABSTRACTPurposeDecreased ADAMTS-13 (A Disintegrin and Metalloprotease with a ThromboSpondin type 1 motif, member 13) seems to be associated with a poor…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis: Description of a Series and Review of the Literature by Gómez-Puerta, Jose A., Peris, Pilar, Reverter, Joan Carles, Espinosa, Gerard, Martinez-Ferrer, Angeles, Monegal, Ana, Monteagudo, Juan, Tàssies, Dolors, Guañabens, Nuria

    Published in Medicine (Baltimore) (01-11-2013)
    “…Multifocal or multiple osteonecrosis (ON), defined by the involvement of 3 or more anatomic sites, is unusual, being observed in only 3%-10% of patients…”
    Get full text
    Journal Article